ISSN: 1859 - 2872
Imaging characteristics of 18F-FDG PET/CT in ovarian cancer recurrence
Main Article Content
Keywords
Abstract
Objective: This study aimed to assess the imaging characteristics of 18F-FDG PET/CT in ovarian cancer recurrence and its correlation with serum CA-125 levels. Subject and method: A combined retrospective and cross-sectional study was conducted on 33 ovarian cancer patients who had undergone debulking surgery and were suspected of recurrence. They underwent 18F-FDG PET/CT scans to determine recurrence. Result: The median age of the study group was 60, predominantly at FIGO stage III prior to debulking treatment. 18F-FDG PET/CT detected lesions in 100% of patients, with the most common metastatic sites are peritonaeum and abdominal lymph nodes. There was no significant difference in SUVmax values at different metastatic sites, and no correlation between SUVmax values and CA-125 levels. Conclusion: 18F-FDG PET/CT plays a significant role in ovarian cancer recurrence, the most common metastatic sites are abdominal lymph nodes, no correlation between PET/CT indices and CA-125 levels
Article Details
References
2. Ushijima K (2010) Treatment for recurrent ovarian cancer-at first relapse. J Oncol: 497429.
3. Kruse V et al (2013) Serum tumor markers and PET/CT imaging for tumor recurrence detection. Ann Nucl Med 27(2): 97-104.
4. Pannu HK et al (2004) PET-CT in recurrent ovarian cancer: initial observations. Radiographics 24(1): 209-223.
5. Gu P et al (2009) CA 125, PET alone, PET–CT, CT and MRI in diagnosing recurrent ovarian carcinoma: A systematic review and meta-analysis. European Journal of Radiology 71(1): 164-174.
6. Palomar Muñoz A et al (2018) Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages. Medicine (Baltimore) 97(17): 0098.
7. Dondi F et al (2022) [18F]FDG PET/CT and CA-125 in the evaluation of ovarian cancer relapse or persistence: Is there any correlation? Nucl Med Rev Cent East Eur 25(2): 78-84.
8. Cengiz A et al (2019) The role of (18)F-FDG PET/CT in detecting ovarian cancer recurrence in patients with elevated CA-125 levels. Mol Imaging Radionucl Ther 28(1): 8-14.
9. Rubini G et al (2014) Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125. Rev Esp Med Nucl Imagen Mol 33(1): 22-27.
10. Wang X, Yang L, and Wang Y (2022) Meta-analysis of the diagnostic value of (18)F-FDG PET/CT in the recurrence of epithelial ovarian cancer. Front Oncol 12: 1003465.
11. Kim CY et al (2015) Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol 136(3): 498-504.
Article Sidebar
